Eva-Lotta Allan to chair Maxion Therapeutics board of directors

Cambridge, UK-based biotech Maxion Therapeutics has announced the appointment of senior industry leader Eva-Lotta Allan as chairwoman of its board of directors.

The announcement comes at an important moment of growth by the company as it advances its lead program towards the clinic, following its  USD $16 million Series A  fundraise earlier this year. The company is developing antibody-based drugs for previously untreatable ion channel- and GPCR-driven diseases,

Ms Allan brings significant experience from life science companies and 30 years of corporate, business development and operational expertise combined with a wealth of partnership experience from the biotech industry. As Immunocore’s (Nasdaq: IMCR) chief business officer (CBO), Ms Allan achieved $320 million Series A fundraising and established significant partnerships with top pharmaceutical companies over five years. Prior to that, she was CBO at Ablynx for seven years, participating in taking the company public and completed several strategic partnerships. She is currently chairwoman of Draupnir Bio, and is non-exec director at Almirall (where she also chairs the Nomination and Remuneration Committee), Aleta BioTherapeutics, and Crescendo Biologics.